Pharmaxis to delist from Nasdaq
This article was originally published in Scrip
Executive Summary
The Australian venture Pharmaxis has decided to delist its shares from the Nasdaq Global Market in the US, citing the cost of regulatory compliance and a lack of clear benefits.